

Dialogues in Contraception[®], Volume 11, Issue 4

References

Please click on the Reference Section below to go directly to that section's reference list. You can also scroll from this page to view all of the references.

Reference Sections

[Sociocultural and Multicultural Issues in Contraceptive Counseling](#)

[Perimenopausal Women and Contraception](#)

[Sexual Interest and Sexual Satisfaction With Hormonal Contraception](#)

Sociocultural and Multicultural Issues in Contraceptive Counseling

1. Nápoles-Springer AM, Santoyo J, Houston K, Pérez-Stable EJ, Stewart AL. Patients' perceptions of cultural factors affecting the quality of their medical encounters. *Health Expect.* 2005;8:4-17.
2. US Census Bureau. List of race or ethnic groups. Available at: http://factfinder.census.gov/home/en/epss/reg_list.html. Accessed September 25, 2007.
3. US Census Bureau. Minority population tops 100 million. <http://www.census.gov/Press-Release/www/releases/archives/population/010048.html>. Accessed September 25, 2007.
4. Blumenthal PD. *Cultural Competency in the Provision of Contraceptive Service Delivery: Overcoming Barriers*. Available at: http://www.contraceptiononline.org/monographs/cultural-competency/cultural_competency.pdf. Accessed September 25, 2007.
5. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982–2002. *Adv Data.* 2004;350:1-35.
6. US Department of Health and Human Services, Office of Minority Health. National standards on culturally and linguistically appropriate services (CLAS). Available at: <http://www.omhrc.gov/templates/browse.aspx?lvl=2&lvlID=15>. Accessed September 25, 2007.
7. Pennachio DL. Caring for your Muslim patients. Stereotypes and misunderstandings affect the care of patients from the Middle East and other parts of the Islamic world. *Med Econ.* 2005;82:46-50.
8. University of Washington Medical Center. Culture Clues™. Communicating with your Korean patient. Available at: http://depts.washington.edu/pfes/pdf/KoreanCultureClue04_07.pdf. Accessed September 7, 2007.
9. University of Washington Medical Center. Culture Clues™. Communicating with your Chinese patient. Available at: http://depts.washington.edu/pfes/pdf/ChineseCultureClue4_07.pdf. Accessed September 7, 2007.

10. University of Washington Medical Center. Culture Clues™. Communicating with your Somali patient. Available at: http://depts.washington.edu/pfes/pdf/SomaliCultureClue4_07.pdf. Accessed September 7, 2007.
11. University of Washington Medical Center. Culture Clues™. Communicating with your Vietnamese patient. Available at: http://depts.washington.edu/pfes/pdf/VietnameseCultureClue4_07.pdf. Accessed September 7, 2007.
12. University of Washington Medical Center. Culture Clues™. Communicating with your Russian patient. Available at: http://depts.washington.edu/pfes/pdf/RussianCultureClue4_07.pdf. Accessed September 7, 2007.
13. University of Washington Medical Center. Culture Clues™. Communicating with your Albanian patient. Available at: http://depts.washington.edu/pfes/pdf/AlbanianCultureClue4_07.pdf. Accessed September 7, 2007.
14. American College of Obstetricians and Gynecologists. Female circumcision/female genital mutilation (FC/FGM) fact sheet. Available at: http://www.acog.org/from_home/departments/dept_notice.cfm?recno=18&bulletin=1081. Accessed September 26, 2007.
15. University of Washington Medical Center. Culture Clues™. Communicating with your American Indian/Alaska Native patient. Available at: http://depts.washington.edu/pfes/pdf/AmericanIndianCultureClue4_07.pdf. Accessed September 7, 2007.
16. Gilliam ML, Warden M, Goldstein C, Tapia B. Concerns about contraceptive side effects among young Latinas: a focus-group approach. *Contraception*. 2004;70:299-305.
17. Wiebe ER, Henderson A, Choi J, Trouton K. Ethnic Korean women's perceptions about birth control. *Contraception*. 2006;73:623-627.
18. Wiebe ER, Sent L, Fong S, Chan J. Barriers to use of oral contraceptives in ethnic Chinese women presenting for abortion. *Contraception*. 2002;65:159-163.
19. Schenker JG, Rabenou V. Contraception: traditional and religious attitudes. *Eur J Obstet Gynecol Reprod Biol*. 1993;49:15-18.
20. Sangi-Haghpeykar H, Ali N, Posner S, Poindexter AN. Disparities in contraceptive knowledge, attitude and use between Hispanic and non-Hispanic whites. *Contraception*. 2006;74:125-132.

21. University of Michigan Health System. Program for reproductive health beliefs. Available at: <http://www.med.umich.edu/Multicultural/ccp/index.htm>. Accessed December 14, 2007.
22. Facione NC, Facione PA. Perceived prejudice in healthcare and women's health protective behavior. *Nurs Res*. 2007;56:175-184.
23. Thorburn S, Bogart LM. Conspiracy beliefs about birth control: barriers to pregnancy prevention among African Americans of reproductive age. *Health Educ Behav*. 2005;32:474-487.
24. Thorburn S. Attitudes toward contraceptive methods among African-American men and women: similarities and differences. *Women's Health Issues*. 2007;17:29-36.
25. Rothschild SK. Cross-cultural issues in primary care medicine. *Dis Mon*. 1998;44:293-319.
26. Betancourt JR, Maina AW. The Institute of Medicine report "Unequal Treatment": implications for academic health centers. *Mt Sinai J Med*. 2004;71:314-321.
27. Unger JB, Molina GB. Acculturation and attitudes about contraceptive use among Latina women. *Health Care Women Int*. 2000;21:235-249.
28. Lieberman LS, Stoller EP, Burg MA. Women's health care: cross-cultural encounters within the medical system. *J Fla Med Assoc*. 1997;84:364-373.
29. Barr DA, Wanat SF. Listening to patients: cultural and linguistic barriers to health care access. *Fam Med*. 2005;37:199-204.
30. National Center for Cultural Competence. Cultural competence: it all starts at the front desk. Available at: <http://www11.georgetown.edu/research/gucchd/nccc/documents/FrontDeskArticle.pdf>. Accessed September 7, 2007.
31. Núñez AE, Robertson C. Multicultural considerations in women's health. *Med Clin North Am*. 2003;87:939-954.
32. Betancourt JR, Green AR, Carrillo JE, Ananeh-Firempong O II. Defining cultural competence: a practical framework for addressing racial/ethnic disparities in health and health care. *Public Health Rep*. 2003;118:293-302.
33. Ngo-Metzger Q, Massagli MP, Clarridge BR, et al. Linguistic and cultural barriers to care. Perspective of Chinese and Vietnamese immigrants. *J Gen Intern Med*. 2003;18:44-52.

34. Flores G. The impact of medical interpreter services on the quality of health care: a systematic review. *Med Care Res Rev.* 2005;62:255-299.
35. Rosenberg E, Leanza Y, Seller R. Doctor-patient communication in primary care with an interpreter: physician perceptions of professional and family interpreters. *Patient Educ Couns.* 2007;67:286-292.
36. University of Washington Medical Center. Culture Clues™. Communicating with your deaf patient. Available at: http://depts.washington.edu/pfes/pdf/DeafCultureClue4_07.pdf. Accessed September 25, 2007.
37. Kim C, Seidel KW, Begier EA, Kwok YS. Diabetes and depot medroxyprogesterone contraception in Navajo women. *Arch Intern Med.* 2001;161:1766-1771.
38. Espey E, Steinhart J, Ogburn T, Qualls C. Depo-Provera associated with weight gain in Navajo women. *Contraception.* 2000;62:55-58.
39. Cutilli CC. Do your patients understand? Providing culturally congruent patient education. *Orthop Nurs.* 2006;25:218-224.

Perimenopausal Women and Contraception

1. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. *NIH Consens State Sci Statements*. 2005;22:1-38.
2. Speroff L. Management of the perimenopausal transition. *Contemporary OB/GYN*. 2000;14-37.
3. Mishell DR Jr. Menopause. In: Stenchever MA, Droegemueller W, Herbst AL, Mishell DR Jr, eds. *Comprehensive Gynecology*. 4th ed. St. Louis, Mo: Mosby Inc.; 1217-1258.
4. Prior JC. The ageing female reproductive axis II: ovulatory changes with perimenopause. *Novartis Found Symp*. 2002;242:172-186.
5. Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. *J Clin Endocrinol Metab*. 1999;84:4025-4030.
6. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. *J Clin Endocrinol Metab*. 1996;81:1495-1501.
7. Barsom SH, Mansfield PK, Koch PB, Gierach G, West SG. Association between psychological stress and menstrual cycle characteristics in perimenopausal women. *Womens Health Issues*. 2004;14:235-241.
8. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. *Menopause*. 2004;11:11-33.
9. Greendale GA, Gold EB. Lifestyle factors: are they related to vasomotor symptoms and do they modify the effectiveness or side effects of hormone therapy? *Am J Med*. 2005;118(suppl 12B):148-154.
10. Hyde Riley E, Inui TS, Kleinman K, Connelly MT. Differential association of modifiable health behaviors with hot flashes in perimenopausal and postmenopausal women. *J Gen Intern Med*. 2004;19:740-746.
11. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. *Obstet Gynecol*. 2003;101:264-272.

12. Randolph JF Jr, Sowers M, Bondarenko I, et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. *J Clin Endocrinol Metab.* 2005;90:6106-6112.
13. Freedman RR. Hot flashes: behavioral treatments, mechanisms, and relation to sleep. *Am J Med.* 2005;118(suppl 12B):124-130.
14. Freedman RR, Roehrs TA. Lack of sleep disturbance from menopausal hot flashes. *Fertil Steril.* 2004;82:138-144.
15. Freedman RR, Roehrs TA. Sleep disturbance in menopause. *Menopause.* 2007;14:826-829.
16. Bromberger JT, Assmann SF, Avis NE, Schocken M, Kravitz HM, Cordal A. Persistent mood symptoms in a multiethnic community cohort of pre- and perimenopausal women. *Am J Epidemiol.* 2003;158:347-356.
17. Cohen LS, Soares CN, Joffe H. Diagnosis and management of mood disorders during the menopausal transition. *Am J Med.* 2005;118(suppl 12B):93-97.
18. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. *Arch Gen Psychiatry.* 2006;63:385-390.
19. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. *Arch Gen Psychiatry.* 2006;63:375-382.
20. Avis NE, Ory M, Matthews KA, Schocken M, Bromberger J, Colvin A. Health-related quality of life in a multiethnic sample of middle-aged women: Study of Women's Health Across the Nation (SWAN). *Med Care.* 2003;41:1262-1276.
21. Santoro N, Lasley B, McConnell D, et al. Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: The Study of Women's Health across the Nation (SWAN) Daily Hormone Study. *J Clin Endocrinol Metab.* 2004;89:2622-2631.
22. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. *Perspect Sex Reprod Health.* 2006;38:90-96.
23. Henshaw SK. Unintended pregnancy in the United States. *Fam Plann Perspect.* 1998;30:24-29, 46.

24. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. *Adv Data*. 2004;350:1-35.
25. US Census Bureau. Most people make only one trip down the aisle, but first marriages shorter, Census Bureau reports. Available at: http://www.census.gov/Press-Release/www/releases/archives/marital_status_livingarrangements/010624.html. Accessed September 21, 2007.
26. Jones RK, Darroch JE, Henshaw SK. Contraceptive use among US women having abortions in 2000-2001. *Perspect Sex Reprod Health*. 2002;34:294-303.
27. Chandra A, Martinez GM, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of US women: data from the 2002 National Survey of Family Growth. *Vital Health Stat* 23. 2005;1-160.
28. Kailas NA, Sifakis S, Koumantakis E. Contraception during perimenopause. *Eur J Contracept Reprod Health Care*. 2005;10:19-25.
29. Speroff L, Darney PD. Clinical guidelines for contraception at different ages: early and late. In: *A Clinical Guide for Contraception*. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:chap 11.
30. Suwikrom S, Jaisamrarn U. Comparison of the metabolic effects of oral contraceptive and nonhormonal contraceptive use in women over 40 years old. *Contraception*. 2005;71:183-187.
31. Duckitt K. Medical management of perimenopausal menorrhagia: an evidence-based approach. *Menopause Int*. 2007;13:14-18.
32. World Health Organization. *Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use*. 3rd ed. Geneva, Switzerland: World Health Organization; 2004.
33. Nelson AL, Stewart FH. Menopause. In: *Contraceptive Technology*. 18th ed. New York, NY: Ardent Media Inc.; 2004.
34. American College of Obstetricians and Gynecologists. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. *Obstet Gynecol*. 2006;107:1453-1472.
35. Kaunitz AM. Oral contraceptive use in perimenopause. *Am J Obstet Gynecol*. 2001;185(suppl):S32-S37.

36. Davis A, Godwin A, Lippman J, Olson W, Kafrisen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. *Obstet Gynecol.* 2000;96:913-920.
37. Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception and bone health: a systematic review. *Contraception.* 2006;73:445-469.
38. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives: a practitioner's guide to meta-analysis. *Hum Reprod.* 1997;12:1851-1863.
39. Cancer and Steroid Hormone Study of the Centers for Disease Control, National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. *JAMA.* 1987;257:796-800.
40. Cancer and Steroid Hormone Study of the Centers for Disease Control, and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. *N Engl J Med.* 1987;316:650-655.
41. Ness RB, Grisso JA, Klapper J, and the SHARE Study Group. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. *Am J Epidemiol.* 2000;152:233-241.
42. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. *Obstet Gynecol.* 1992;80:708-714.
43. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. *BMJ.* 2007;335:621-622.
44. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. *N Engl J Med.* 1996;335:8-15.
45. Schwartz SM, Petitti DB, Siscovick DS, et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. *Stroke.* 1998;29:2277-2284.
46. World Health Organization. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. *World Health Organ Tech Rep Ser.* 1998;877:i-89.

47. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. *Br Med J*. 1989;298:165-168.
48. Matthews KA, Santoro N, Lasley B, et al. Relation of cardiovascular risk factors in women approaching menopause to menstrual cycle characteristics and reproductive hormones in the follicular and luteal phases. *J Clin Endocrinol Metab*. 2006;91:1789-1795.
49. Alušík S, Paluch Z, Jedličková V. The influence of long-term hormonal contraception and smoking on plasma concentrations of nitrites and nitrates. *Med Sci Monit*. 2005;11:BR61-BR64.
50. Benowitz NL, Lesov-Schlaggar CN, Swan GE, Jacob P III. Female sex and oral contraceptive use accelerate nicotine metabolism. *Clin Pharmacol Ther*. 2006;79:480-488.
51. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. *N Engl J Med*. 2002;346:2025-2032.
52. Silvera SA, Miller AB, Rohan TE. Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. *Cancer Causes Control*. 2005;16:1059-1063.
53. Murray PP, Stadel BV, Schlesselman JJ. Oral contraceptive use in women with a family history of breast cancer. *Obstet Gynecol*. 1989;73:977-983.
54. Milne RL, Knight JA, John EM, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of *BRCA1* and *BRCA2* mutations. *Cancer Epidemiol Biomarkers Prev*. 2005;14:350-356.
55. Gill JK, Press MF, Patel AV, Bernstein L. Oral contraceptive use and risk of breast carcinoma in situ (United States). *Cancer Causes Control*. 2006;17:1155-1162.
56. Archer DF. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. *Contraception*. 2006;74:359-366.
57. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary--ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. *Contraception*. 2006;74:100-103.
58. Steinauer J, Autry AM. Extended cycle combined hormonal contraception. *Obstet Gynecol Clin North Am*. 2007;34:43-55.

59. Stewart FH, Kaunitz AM, LaGuardia KD, Karvois DL, Fisher AC, Friedman AJ, for the ORTHO EVRA Extended Regimen Study Group. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. *Obstet Gynecol.* 2005;105:1389-1396.
60. Booranabunyat S, Taneepanichskul S. Implanon use in Thai women above the age of 35 years. *Contraception.* 2004;69:489-491.
61. Croxatto HB, Urbancsek J, Massai R, Bennink HC, van Beek A, and the Implanon® Study Group. A multicentre efficacy and safety study of the single contraceptive implant Implanon®. *Hum Reprod.* 1999;14:976-981.
62. Otero Flores JB, Balderas ML, Bonilla MC, Vázquez-Estrada L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. *Int J Gynaecol Obstet.* 2005;90:228-233.
63. Smith OP, Critchley HO. Progestogen only contraception and endometrial break through bleeding. *Angiogenesis.* 2005;8:117-126.
64. d'Arcangues C. Management of vaginal bleeding irregularities induced by progestin-only contraceptives. *Hum Reprod.* 2000;15(suppl 3):24-29.
65. Speroff L, Darney PD. Implant contraception. In: *A Clinical Guide for Contraception.* 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:chap 5.
66. Speroff L, Darney PD. Injectable contraception. In: *A Clinical Guide for Contraception.* 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:chap 6.
67. Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. *Contraception.* 2006;74:234-238.
68. Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDs. *Contraception.* 1991;44:473-480.
69. Gebbie A. Contraception in the perimenopause. *J Br Menopause Soc.* 2003;9:123-128.
70. Taneepanichskul S, Dusitsin N. Contraception in perimenopause. *J Med Assoc Thai.* 2003;86(suppl 2):S140-S144.
71. Sturdee D. Levonorgestrel intrauterine system for endometrial protection [review]. *J Br Menopause Soc.* 2006;12(suppl 1):1-3.

72. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)—a systematic enquiry and overview. *Eur J Obstet Gynecol Reprod Biol.* 2005;125:9-28.
73. Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. *Fertil Steril.* 1997;68:426-429.
74. United Nations Development Programme, United Nations Population Fund, World Health Organization, World Bank, Special Programme of Research, Development and Research Training in Human Reproduction. Long-term reversible contraception: twelve years of experience with the TCU380A and TCU220C. *Contraception.* 1997;56:341-352.
75. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. *Contraception.* 2007;75(suppl):S70-S75.
76. Inki P. Long-term use of the levonorgestrel-releasing intrauterine system. *Contraception.* 2007;75(suppl):S161-S166.
77. Strom BL, Berlin JA, Weber AL, et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. *Contraception.* 2004;69:353-360.
78. Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. *Obstet Gynecol.* 2005;106:813-817.
79. Castellsagué X, Thompson WD, Dubrow R. Intra-uterine contraception and the risk of endometrial cancer. *Int J Cancer.* 1993;54:911-916.
80. Hill DA, Weiss NS, Voigt LF, Beresford SAA. Endometrial cancer in relation to intra-uterine device use. *Int J Cancer.* 1997;70:278-281.
81. Lasisse DL, Savitz DA, Hamman RF, Barón AE, Brinton LA, Levines RS. Invasive cervical cancer and intrauterine device use. *Int J Epidemiol.* 1991;20:865-870.
82. Parazzini F, La Vecchia C, Moroni S. Intrauterine device use and risk of endometrial cancer. *Br J Cancer.* 1994;70:672-673.
83. Parazzini F, La VC, Negri E. Use of intrauterine device and risk of invasive cervical cancer. *Int J Epidemiol.* 1992;21:1030-1031.
84. Curtis KM, Marchbanks PA, Peterson HB. Neoplasia with use of intrauterine devices. *Contraception.* 2007;75(suppl 6):S60-S69.

85. Varila E, Wahlström T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. *Fertil Steril*. 2001;76:969-973.
86. Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri- and postmenopausal women. *Contraception*. 2007;75(suppl 6):S155-S160.
87. Hampton NR, Rees MC, Lowe DG, Rauramo I, Barlow D, Guillebaud J. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. *Hum Reprod*. 2005;20:2653-2660.
88. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. *Contraception*. 2006;74:90-99.
89. Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal postmenopausal women. *Clin Endocrinol (Oxf)*. 1998;49:615-618.
90. Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. *Contraception*. 2006;73:470-487.
91. Arslan AA, Zeleniuch-Jacquotte A, Lukanova A, Rinaldi S, Kaaks R, Toniolo P. Reliability of follicle-stimulating hormone measurements in serum. *Reprod Biol Endocrinol*. 2003;1:49.
92. Randolph JF Jr, Sowers M, Bondarenko IV, Harlow SD, Luborsky JL, Little RJ. Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. *J Clin Endocrinol Metab*. 2004;89:1555-1561.

Sexual Interest and Sexual Satisfaction With Hormonal Contraception

1. Basson R. Hormones and sexuality: current complexities and future directions. *Maturitas*. 2007;57:66-70.
2. Schaffir J. Hormonal contraception and sexual desire: a critical review. *J Sex Marital Ther*. 2006;32:305-314.
3. Sexual and gender identity disorders. In: *Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR*[®]. 4th ed. Text revision. Washington, DC: American Psychiatric Association; 2000.
4. Basson R, Leiblum S, Brotto L, et al. Revised definitions of women's sexual dysfunction. *J Sex Med*. 2004;1:40-48.
5. DeCherney AH. Hormone receptors and sexuality in the human female. *J Womens Health Gend Based Med*. 2000;9(suppl 1):S9-S13.
6. Alexander GM, Sherwin BB, Bancroft J, Davidson DW. Testosterone and sexual behavior in oral contraceptive users and nonusers: a prospective study. *Horm Behav*. 1990;24:388-402.
7. Basson R. Clinical practice. Sexual desire and arousal disorders in women. *N Engl J Med*. 2006;354:1497-1506.
8. Gallicchio L, Schilling C, Tomic D, Miller SR, Zacur H, Flaws JA. Correlates of sexual functioning among mid-life women. *Climacteric*. 2007;10:132-142.
9. Martin-Loeches M, Ortí RM, Monfort M, Ortega E, Rius J. A comparative analysis of the modification of sexual desire of users of oral hormonal contraceptives and intrauterine contraceptive devices. *Eur J Contracept Reprod Health Care*. 2003;8:129-134.
10. Burger HG, Papalia M-A. A clinical update on female androgen insufficiency—testosterone testing and treatment in women presenting with low sexual desire. *Sex Health*. 2006;3:73-78.
11. Bullivant SB, Sellergren SA, Stern K, et al. Women's sexual experience during the menstrual cycle: identification of the sexual phase by noninvasive measurement of luteinizing hormone. *J Sex Res*. 2004;41:82-93.
12. Anastasiadis AG, Davis AR, Salomon L, Burchardt M, Shabsigh R. Hormonal factors in female sexual dysfunction. *Curr Opin Urol*. 2002;12:503-507.

13. van Lunsen RHW, Laan E. Genital vascular responsiveness and sexual feelings in midlife women: psychophysiological, brain, and genital imaging studies. *Menopause*. 2004;11:741-748.
14. Pauls RN, Kleeman SD, Karram MM. Female sexual dysfunction: principles of diagnosis and therapy. *Obstet Gynecol Surv*. 2005;60:196-205.
15. Turna B, Apaydin E, Semerci B, Altay B, Cikili N, Nazli O. Women with low libido: correlation of decreased androgen levels with female sexual function index. *Int J Impot Res*. 2005;17:148-153.
16. Bachmann G, Bancroft J, Braunstein G, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. *Fertil Steril*. 2002;77:660-665.
17. Speroff L, Fritz MA. Hirsutism. In: Speroff L, Fritz MA, eds. *Clinical Gynecologic Endocrinology and Infertility*. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004:499-503.
18. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. *JAMA*. 2005;294:91-96.
19. Santoro N, Torrens J, Crawford S, et al. Correlates of circulating androgens in mid-life women: the Study of Women's Health Across the Nation (SWAN). *J Clin Endocrinol Metab*. 2005;90:4836-4845.
20. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. *N Engl J Med*. 2000;343:682-688.
21. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. *Psychosom Med*. 1985;47:339-351.
22. Graham CA, Bancroft J, Doll HA, Greco T, Tanner A. Does oral contraceptive-induced reduction in free testosterone adversely affect the sexuality or mood of women? *Psychoneuroendocrinology*. 2007;32:246-255.
23. Greco T, Graham CA, Bancroft J, Tanner A, Doll HA. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 µg of ethinyl estradiol. *Contraception*. 2007;76:8-17.
24. Drillich A, Davis SR. Androgen therapy in women: what we think we know. *Exp Gerontol*. 2007;42:457-462.

25. Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. *Menopause*. 2006;13:770-779.
26. Oranratanaphan S, Taneepanichskul S. A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido. *J Med Assoc Thai*. 2006;89(suppl 4):S17-S22.
27. Caruso S, Agnello C, Intelisano G, et al. Prospective study on sexual behavior of women using 30 µg ethinylestradiol and 3 mg drospirenone oral contraceptive. *Contraception*. 2005;72:19-23.
28. Caruso S, Agnello C, Intelisano G, Farina M, Di Mari L, Cianci A. Sexual behavior of women taking low-dose oral contraceptive containing 15 µg ethinylestradiol/60 µg gestodene. *Contraception*. 2004;69:237-240.
29. Sanders SA, Graham CA, Bass JL, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. *Contraception*. 2001;64:51-58.
30. Graham CA, Ramos R, Bancroft J, Maglaya C, Farley TMM. The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. *Contraception*. 1995;52:363-369.
31. Westhoff CL, Heartwell S, Edwards S, et al. Oral contraceptive discontinuation: do side effects matter? *Am J Obstet Gynecol*. 2007;196:412.e1-412.e7.
32. Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. *Contraception*. 2007;76:267-272.
33. NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) [package insert]. Roseland, NJ: Organon USA Inc.; 2005.